FY2025 · ended Dec 31, 2025 · Revenue $500,000 · Filed Mar 19, 2026
Mereo Biopharma Group PLC (MREO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $500,000 and a net loss of $41.9 million. Free cash flow was -$31.0 million. As of Jun 30, 2026 it held $30.1 million in cash and investments and $1.0 million in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-28.10M
+43.3% vs year-ago TTM
Operating cash flow (TTM)
$-25.35M
+23.0% vs year-ago TTM
Free cash flow (TTM)
$-25.35M
EPS (TTM)
$-0.04
+44.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
798.08M
+0.4% vs prior year
Net cash
$29.09M
as of Jun 30, 2026
Operating margin
-8021.4%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MREO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719714
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Revenue | $500,000 | $0 | $10.0M |
| Operating income | -$40.1M | -$47.4M | -$28.4M |
| Net income | -$41.9M | -$43.3M | -$29.5M |
| Diluted EPS | -$0.05 | -$0.06 | -$0.04 |
| Operating cash flow | -$31.0M | -$32.8M | -$21.1M |
| Free cash flow | -$31.0M | — | -$21.1M |
| Total assets | $45.9M | $76.4M | $66.5M |
| Total liabilities | $5.0M | $15.4M | $16.0M |
| Stockholders' equity | $40.9M | $61.0M | $50.5M |
| Cash and investments | $41.0M | $69.8M | $57.4M |
| Total debt | $202,000 | $894,000 | $1.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Aug 19, 2026 | Aug 18, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 14, 2026 | May 14, 2026 |
| 8-K/A |
Amended current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 439 Mereo Biopharma Group PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.